Matthew M. Wielgosz

Matthew M. Wielgosz

Auto-generated profile, based on publicly available information

Matthew M. Wielgosz

Vector Development and Production Laboratory, St. Jude Children’s Research Hospital, Memphis, TN, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2020 in Gene Therapy
Verified
Journal Article
Open access
PDF file
YJYoonjeong Jang
Yoonjeong Jang
YKYoon-Sang Kim
Yoon-Sang Kim
MWMatthew M. Wielgosz
Matthew M. Wielgosz
FRANCESCA FERRARAFRANCESCA FERRARA
FRANCESCA FERRARA
ZMZhijun Ma
Zhijun Ma
BRByoung Y. Ryu
Byoung Y. Ryu
Autologous gene therapy using lentiviral vectors (LVs) holds promise for treating monogenetic blood diseases. However, clinical applications can be limited by suboptimal hematopoietic stem cell (HSC) transduction and insufficient quantities of available vector. We recently reported gene therapy for X-linked severe combined immunodeficiency using a protocol in which patient CD34+ cells were incubated with two successive transductions. Here we describe an improved protocol for LV delivery to CD34+ cells that simplifies product manipulation, reduces vector consumption, and achieves greater vector copy number (VCN) of repopulating HSCs in mouse xenotransplantation assays. Notable findings include the following: (1) the VCN of CD34+ cells measured shortly after transduction did not always correlate with the VCN of repopulating HSCs after xenotransplantation; (2) single-step transduction at higher CD34+ cell concentrations (2–4 × 106/ml) conserved LV without compromising HSC VCN; (3) poloxamer F108 (LentiBOOST) increased HSC VCN by two- to threefold (average from three donors); (4) although LentiBOOST + prostaglandin E2 combination further increased VCN in vitro, the VCN observed in vivo were similar to LentiBOOST alone; (5) cyclosporine H increased the HSC VCN to a similar or greater extent with LentiBOOST in vivo. Our findings delineate an improved protocol to increase the VCN of HSCs after CD34+ cell transduction with clinically relevant LVs.

28 April 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
NUNaoya Uchida
Naoya Uchida
FRANCESCA FERRARAFRANCESCA FERRARA
FRANCESCA FERRARA
CDClaire M. Drysdale
Claire M. Drysdale
MYMorgan Yapundich
Morgan Yapundich
JGJackson Gamer
Jackson Gamer
JTJohn F. Tisdale
John F. Tisdale
In xenograft mice and nonhuman primates, BCL11A interference and coexpression of a truncated erythropoietin receptor led to sustained hemoglobin F.

1 May 2026 in Science Advances
Verified
Journal Article
Open access
KBKHADIJA BANU
KHADIJA BANU
MKMohammad Aslam Khan
Mohammad Aslam Khan
SLSihan Li
Sihan Li
MRMorgan Reynolds-Gagliano
Morgan Reynolds-Gagliano
XWXiaofei Wang
Xiaofei Wang
SBSamuel W. Brady
Samuel W. Brady
Cancer therapeutics frequently fail in clinical trials because of poor therapeutic index (efficacy-to-toxicity ratio). We systematically identified targets likely to have a good therapeutic index, revealing insulin receptor substrate 4 (IRS4) as a dependency in IRS4 -expressing cancers. Pan-cancer analysis of pediatric-enriched cancers revealed IRS4 expression consistent with dependency in 68% of choroid plexus, 37% of malignant rhabdoid, 31% of NUT midline, and 5% of osteosarcomas, while in adult cancers, it was expressed in 8% of uterine leiomyosarcomas and 1 to 2% of lung squamous, stomach, and breast carcinomas. IRS4 expression in adult tumors was associated with enhancer hijacking rearrangements, including recurrent GATA3-IRS4 and ANKRD30A-IRS4 in breast cancer, while rhabdoid and NUT midline cancers expressed IRS4 epigenetically. IRS4 fueled cancer dependency through PI3K-Akt activation, and domain analysis revealed the PH and PTB domains, which have a predicted drug pocket, to be dispensable, suggesting degradation-based modalities. These data reveal IRS4 as a target in IRS4-expressing cancers and suggest inhibitory approaches.